Virbac Evolves Its Board of Directors: A Censor and a New Audit Committee Member
The veterinary laboratory based in Carros has evolved the composition of its board of directors, effective September 17, 2026. Two changes are involved: the arrival of a censor and the strengthening of the audit committee.
Eline Madelpuech Joins the Board with Consultative Voice
On September 17, 2026, Eline Madelpuech was appointed censor to the board of directors of Virbac. As a censor, she participates in meetings with a consultative voice.
Holder of a master's degree in medicine from the University of Liège (specialization in general medicine) and an MBA from INSEAD, she is also the granddaughter of the Group's founder. She brings to the board her medical expertise as well as her experience in strategy and commercial development acquired within a human health laboratory.
Olivier Charmeil Joins the Audit Committee
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Olivier Charmeil, already an independent director and member of the nominations and remuneration committee, joins the audit committee of Virbac. This committee is composed of Philippe Capron (chairman), Pierre Madelpuech and Cyrille Petit.
The audit committee's role is to ensure the quality and reliability of the Group's financial, accounting and sustainability information. It also ensures the effectiveness of internal control systems, risk management and compliance programs.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 768 millions d'euros
Quarterly revenue: 768 millions d'euros
Net income: 87,4 millions d'euros
195,9 millions d'euros
Guidance from the release
« Objectifs 2026 confirmés, dans la borne haute de la fourchette »
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos objectifs pour l'ensemble de l'année 2026 restent inchangés, notre forte dynamique du premier semestre (+7,4 % de croissance) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires, comprise entre 5,5 % et 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
